RareResearch.AI
← Back to atlas

S334R

Category 3/4 — Most DruggableUncertain significanceTransmembrane · predictedSource card
SerineArginine at position 334 · Cytoplasmic loop 1 · WFS1 (Wolframin)

Interactive 3D Structure

Wild-type reference
Wild-type S334 — hydrogen bond to F330
Fullscreen ↗
DynaMut2 mutant · S334R
Mutant R334 — hydrogen bond to F331 lost (3 contacts lost)
Fullscreen ↗

Bond changes · DynaMut2 interaction analysis

3 lost1 gained4 preserved
Interaction typeWild-type partnerMutant partnerStatus
Hydrogen bondF330F330Preserved
Hydrogen bondF331Lost
Polar contactF330F330Preserved
Polar contactF331Lost
Polar contactI332I332Preserved
Polar contactL336Gained
Van der WaalsF331Lost
Van der WaalsI332I332Preserved

Lost / gained / preserved interatomic contacts at the variant residue, from the DynaMut2 (Arpeggio) interaction analysis of the wild-type and energy-minimized mutant structures.

Computational Predictions

DynaMut2 ΔΔG
-0.19kcal/mol
Destabilising — mild
AlphaMissense
0.986
likely pathogenic
AlphaFold pLDDT
68
model confidence
Schema
Cat 3/4
Category 3/4 — Most Druggable

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Associated conditionsInborn genetic diseases
Population frequency (gnomAD v4)Ultra-rare · AF 0.00025%
cDNA changec.1002C>G
ClinVar accessionVCV001331236
Last evaluated2025/05/19 00:00

Observed at very low frequency in gnomAD.

Full Variant Card

WFS1 Wolframin — S334R Variant Card

Molecular Atlas Pilot · RareResearch.AI · Generated by wolfram-variant-card skill

Serine → Arginine at position 334. Cytoplasmic loop 1. ClinVar Uncertain significance, AlphaMissense 0.986, DynaMut2 ΔΔG -0.19 kcal/mol (destabilising).


Identity

FieldValue
VariantS334R (p.Serine334Arginine)
DNA changec.1002C>G
Gene · ProteinWFS1 · Wolframin (890 aa)
UniProtO76024 · WFS1_HUMAN
ClinVar accessionVCV001331236
Amino acid changeSerine (S) → Arginine (R)

Structural Context

FieldValue
AlphaFold modelAF-O76024-F1, v6
pLDDT at residue 33468.25 — confident
DomainCytoplasmic loop 1
Position contextLoop region · position 334 sits between transmembrane segments, solvent-accessible
IDR flagNo — pLDDT above 50 threshold

UniProt features at this position:

(none catalogued)

Position 334 sits in a connecting loop between transmembrane helices. Loop residues are typically solvent-exposed and often contribute to interhelical contacts or serve as recognition sites for binding partners. The wild-type residue is small polar (serine — hydroxyl); the mutant is positively charged (arginine — guanidinium, strong H-bond donor). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.


Computational Predictions

AlphaMissense

FieldValue
am_pathogenicity0.9856
am_classlikely pathogenic
InterpretationLikely pathogenic (threshold 0.564)

DynaMut2

FieldValue
ΔΔG (kcal/mol)-0.19 (Destabilising)
Job ID178092089777
Result URLhttps://biosig.lab.uq.edu.au/dynamut2/results_prediction/178092089777

Clinical Evidence

FieldValue
ClassificationUncertain significance
Review statuscriteria provided, multiple submitters, no conflicts
Last evaluated2025/05/19 00:00
InheritanceInheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscapeS334R is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 catalogued in ClinVar)
  • Inborn genetic diseases

Research Path Decision Tree

ΔΔG < 2  + binding site affected   →  CATEGORY 3 — docking experiments
ΔΔG 2–4                            →  CATEGORY 2 — pharmacological chaperones
ΔΔG > 4                            →  CATEGORY 1 — gene therapy
pLDDT < 50                         →  CATEGORY 5 — IDR, experimental only
Stable fold + functional site hit  →  CATEGORY 4 — site-specific docking

Final Schema Categorization

Category 3/4 — Most Druggable

<strong>Category 3/4 — Most Druggable</strong><br/><br/>|ΔΔG|=0.19 < 2 kcal/mol (fold intact) + AlphaMissense 0.986 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Why this card matters. Wolframin's fold survives this substitution (|ΔΔG|=0.19 kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.986. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.


Files in this folder

  • AF-O76024-F1-model_v6.pdb — AlphaFold structure
  • S334R_molstar_viewer.html — interactive 3D viewer (auto-highlights position 334 with ball-and-stick + neighbors within 5Å)
  • S334R_variant_card.md — this card (source of truth)
  • S334R_variant_card.html — styled printable card
  • S334R_dynamut2_summary.html — clean offline DynaMut2 result card
  • dynamut2_result.json — structured result data
  • dynamut2_result_page.html — local snapshot of the Biosig result page (asset URLs absolutized)
  • S334R_wildtype_interactions.pse / S334R_mutant_interactions.pse — PyMOL sessions

Generated by wolfram-variant-card skill · RareResearch.AI Molecular Atlas Every assumption documented. Every score sourced.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the S334R PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download S334R PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.